JNK Inhibition Overcomes Resistance of Metastatic Tetraploid Cancer Cells to Irradiation-Induced Apoptosis

Mohamed Jemaà1,2,3, Nouha Setti Boubaker4,5, Nesrine Kerkeni1

  • 1Human Genetics Laboratory LR99ES10, Faculty of Medicine of Tunis, Tunis El Manar University, Tunis 2092, Tunisia.

Insights

Tetraploid cancer cells often resist radiotherapy. Combining SP600125 with irradiation overcomes this resistance by inhibiting the JNK pathway, offering a new strategy for cancer treatment.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Tetraploidy, a doubling of chromosomes, causes genomic instability in tumors.
  • This instability contributes to metastasis and resistance to treatments like radiotherapy.
  • Developing strategies to sensitize tetraploid cells to therapy is crucial.

Purpose of the Study:

  • To investigate the efficacy of combining SP600125, a kinase inhibitor, with irradiation.
  • To evaluate this combination's effect on diploid versus metastatic tetraploid colon cancer cells.
  • To identify the molecular pathways mediating sensitivity to this combined treatment.

Main Methods:

  • In vitro study using RKO colon cancer clones (diploid and tetraploid).
  • Assessed cell cycle, mitochondrial potential, and cell death via flow cytometry.
  • Clonogenic assays evaluated cell sensitivity; KINOMEscan library screened kinase targets.

Main Results:

  • The combination of SP600125 and irradiation overcame radiation resistance in metastatic tetraploid clones.
  • Key kinases inhibited by SP600125 included JNK1, PLK4, and TTK.
  • Sensitivity was linked to DNA damage repair, radiation resistance, and apoptosis pathways via JNK inhibition.

Conclusions:

  • Combined SP600125 and radiotherapy treatment reduces resistance in metastatic tetraploid cancer cells.
  • JNK pathway inhibition is the primary mechanism underlying this enhanced sensitivity.
  • This approach shows promise for overcoming radioresistance in tetraploid cancers.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
832